ProFound Gets Gates Foundation Investment for AI Maternal Health Research
ProFound Therapeutics has received an investment commitment of up to $35 million from the Gates Foundation, including an initial $20 million, to support AI based research into preeclampsia and eclampsia, the company announced in a press release.
The funding will support ProFound Therapeutics' ProFoundry platform and agentic AI capabilities. The company plans to use the platform to identify new biomarkers, protein drugs, and drug targets linked to preeclampsia and eclampsia.
ProFound will study proteins from the expanded human proteome that are expressed in placenta and serum samples from women with the conditions. The work also includes creation of an AI tool specific to preeclampsia and eclampsia.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Enterprise
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
2025 Generative AI in Professional Services Report
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read more